Nantahala Capital Management
VC Fund
New Canaan, United States
Nantahala Capital Management is a hedge fund.
- Total investments:
- 60
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Nantahala Capital Management invests in
BiotechnologyHealth CarePharmaceuticalMedicalTherapeutics
Stages Nantahala Capital Management invests in
Post-IPO EquitySeries BSeries CPost-IPO DebtVenture - Series Unknown
Countries Nantahala Capital Management invests in
United StatesCanadaIsraelFranceNorway
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Paul Rehm
|
|||
Wilmot Harkey
|
|||
Investment Focus
Industry
- Biotechnology 44 (73%)
- Health Care 35 (58%)
- Pharmaceutical 20 (33%)
- Medical 18 (30%)
- Therapeutics 17 (28%)
Stage
- Post-IPO Equity 48 (80%)
- Series B 1 (2%)
- Series C 1 (2%)
- Post-IPO Debt 1 (2%)
- Venture - Series Unknown 1 (2%)
Country
- United States 43 (72%)
- Canada 2 (3%)
- Israel 2 (3%)
- France 1 (2%)
- Norway 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Paul Rehm
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
Wilmot Harkey
Founder & Partner
|
Founder & Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Femasys
|
Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patientcare and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting. | $30M / Post-IPO Equity / Aug 07, 2026 | |
Cellectar Biosciences
|
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M / Post-IPO Equity / May 05, 2026 | |
|
Cellectar Biosciences
|
Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M / Post-IPO Equity / May 05, 2026 | |
Valneva
|
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | |
Azitra
|
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $31M / Post-IPO Equity / Mar 19, 2026 | |
Korro Bio
|
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $85M / Post-IPO Equity / Mar 09, 2026 | |
LB Pharmaceuticals
|
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $100M / Post-IPO Equity / Feb 05, 2026 | |
Curis
|
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previousexperiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com. | $80.8M / Post-IPO Equity / Jan 07, 2026 | |
TELA Bio
|
TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $13M / Post-IPO Equity / Nov 13, 2025 | |
Opus Genetics(formerly Ocuphire Pharma)
|
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $23M / Post-IPO Equity / Nov 06, 2025 | |
| See all 60 investments → | |||
Co-Investors
Stonepine Capital Management
13 deals together
Perceptive Advisors
12 deals together
Samsara BioCapital
7 deals together
Balyasny Asset Management
6 deals together
Biotechnology Value Fund
6 deals together
OrbiMed
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Nantahala Capital Management invest in?
Nantahala Capital Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series B stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nantahala Capital Management?
Public channels for Nantahala Capital Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nantahala Capital Management?
The team at Nantahala Capital Management includes Paul Rehm (Chief Operating Officer) and Wilmot Harkey (Founder & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
